ICOTYDE is the first and only IL-23R targeted oral peptide that delivers complete skin clearance and a favorable safety profile in a once-daily pillApproval supported by four phase 3 studies that met ...
ORKA-001 EVERLAST-A 16-week data now expected in 2Q 2026 following rapid enrollment, with longer-term follow-up data expected in 2H ...
Eli Lilly’s phase 3 ADorable-1 trial of Ebglyss in paediatric patients with moderate-to-severe atopic dermatitis meets primary and key secondary endpoints: Indianapolis Tuesday, ...
Thousands of Oklahomans evacuated Sunday as wildfires spread across the state, fueled by strong winds and high temps. Here's ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results